Jason Gotlib

31.2k total citations · 3 hit papers
297 papers, 11.0k citations indexed

About

Jason Gotlib is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Jason Gotlib has authored 297 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Hematology, 165 papers in Genetics and 101 papers in Rheumatology. Recurrent topics in Jason Gotlib's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (135 papers), Chronic Myeloid Leukemia Treatments (93 papers) and Eosinophilic Disorders and Syndromes (90 papers). Jason Gotlib is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (135 papers), Chronic Myeloid Leukemia Treatments (93 papers) and Eosinophilic Disorders and Syndromes (90 papers). Jason Gotlib collaborates with scholars based in United States, Germany and France. Jason Gotlib's co-authors include James L. Zehnder, Catriona Jamieson, Andreas Reiter, Carol D. Jones, William Shomali, Tracy I. George, Ruben A. Mesa, Ayalew Tefferi, Irving L. Weissman and Srđan Verstovšek and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Jason Gotlib

283 papers receiving 10.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML

2004 1.1k citations Catriona Jamieson, James L. Zehnder et al. profile →
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes

2012 457 citations Peter Valent, Hans‐Peter Horny et al. Journal of Allergy and Clinical Immunology profile →
OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML

2013 356 citations Julia E. Maxson, Jason Gotlib et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason Gotlib United States	51	5.3k	5.0k	4.0k	4.0k	2.3k	297	11.0k
D. Gary Gilliland United States	62	8.1k 1.5×	4.2k 0.8×	2.0k 0.5×	8.4k 2.1×	2.1k 0.9×	126	16.2k
Omar Abdel‐Wahab United States	68	7.4k 1.4×	5.3k 1.1×	1.4k 0.4×	10.9k 2.7×	1.9k 0.8×	306	18.6k
Justus Duyster Germany	52	3.5k 0.7×	2.2k 0.4×	851 0.2×	3.9k 1.0×	1.5k 0.6×	261	9.0k
Marco Cicardi Italy	59	2.9k 0.5×	9.4k 1.9×	3.7k 0.9×	1.2k 0.3×	2.4k 1.0×	230	10.9k
Claus R. Bartram Germany	48	4.1k 0.8×	2.1k 0.4×	681 0.2×	3.8k 1.0×	1.1k 0.5×	212	10.0k
Alessandro M. Vannucchi Italy	78	14.8k 2.8×	19.2k 3.9×	7.7k 1.9×	12.1k 3.1×	992 0.4×	549	23.0k
Jeffrey Tyner United States	46	2.9k 0.5×	2.1k 0.4×	509 0.1×	3.3k 0.8×	1.3k 0.6×	238	7.1k
Uwe Platzbecker Germany	54	8.8k 1.6×	4.1k 0.8×	417 0.1×	3.6k 0.9×	1.4k 0.6×	543	11.3k
Dolors Colomer Spain	60	2.7k 0.5×	4.9k 1.0×	573 0.1×	5.1k 1.3×	2.5k 1.1×	280	12.0k
Anna Porwit Sweden	34	4.4k 0.8×	2.6k 0.5×	529 0.1×	2.2k 0.6×	877 0.4×	173	7.3k

Countries citing papers authored by Jason Gotlib

Since Specialization

Citations

This map shows the geographic impact of Jason Gotlib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Gotlib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Gotlib more than expected).

Fields of papers citing papers by Jason Gotlib

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Gotlib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Gotlib. The network helps show where Jason Gotlib may publish in the future.

Co-authorship network of co-authors of Jason Gotlib

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Gotlib. A scholar is included among the top collaborators of Jason Gotlib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Gotlib. Jason Gotlib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nair, Pramod C., Jacob Piehler, Denis Tvorogov, et al.. (2023). Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. Blood Cancer Discovery. 4(5). 352–364. 12 indexed citations

Liu, Yi, Jason Wu, Kanagavel Murugesan, et al.. (2023). Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens. Blood Advances. 7(18). 5433–5445. 3 indexed citations

Pemmaraju, Naveen, Marina Kremyanskaya, Andrew Kuykendall, et al.. (2023). MPN-541 Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera With the Hepcidin Mimetic, Rusfertide: Blinded Randomized Withdrawal Results of the Phase 2 Revive Study. Clinical Lymphoma Myeloma & Leukemia. 23. S400–S401.

Jutzi, Jonas S., Anna E. Marneth, Ángel Guerra-Moreno, et al.. (2022). Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. Blood. 140(11). 1291–1304. 11 indexed citations

Valent, Peter, Cem Akin, Karin Hartmann, et al.. (2022). Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?. Journal of Allergy and Clinical Immunology. 149(6). 1866–1874. 17 indexed citations

Naumann, Nicole, Johannes Lübke, William Shomali, et al.. (2021). Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto‐oncogene, receptor tyrosine kinase (KIT) D816V mutations. British Journal of Haematology. 194(2). 344–354. 9 indexed citations

Azizi, Armon, Asiri Ediriwickrema, Shyam A. Patel, et al.. (2020). Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia & lymphoma. 61(11). 2700–2707. 18 indexed citations

Cui, Lu, Ignacio Moraga, Tristan Lerbs, et al.. (2020). Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors. Proceedings of the National Academy of Sciences. 118(2). 20 indexed citations

Salama, Mohamed E., Karin Hartmann, Gregor Eisenwort, et al.. (2018). Variability of PD-L1 expression in mastocytosis. Blood Advances. 2(3). 189–199. 7 indexed citations

10.

Shoura, Massa J., Idan Gabdank, Loren Hansen, et al.. (2017). Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiens. G3 Genes Genomes Genetics. 7(10). 3295–3303. 79 indexed citations

11.

Mesa, Ruben A., Jean‐Jacques Kiladjian, John Catalano, et al.. (2017). SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis. Journal of Clinical Oncology. 35(34). 3844–3850. 238 indexed citations

12.

Hinds, David A., Kimberly E. Barnholt, Ruben A. Mesa, et al.. (2016). Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood. 128(8). 1121–1128. 171 indexed citations

13.

Maxson, Julia E., Samuel B. Luty, Jason D. MacManiman, et al.. (2015). The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clinical Cancer Research. 22(3). 757–764. 37 indexed citations

14.

Jamieson, Catriona, Robert P. Hasserjian, Jason Gotlib, et al.. (2015). Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. Journal of Translational Medicine. 13(1). 294–294. 31 indexed citations

15.

Tyner, Jeffrey, Armand Bankhead, Guang Fan, et al.. (2012). Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. Cancer Research. 73(1). 285–296. 100 indexed citations

16.

O’Brien, Susan, Camille N. Abboud, Mojtaba Akhtari, et al.. (2012). Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 10(1). 64–110. 20 indexed citations

17.

McClellan, James Scott, Holbrook E. Kohrt, Steven Coutré, et al.. (2011). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 97(1). 133–136. 101 indexed citations

18.

Pardanani, Animesh, Jason Gotlib, Catriona Jamieson, et al.. (2011). Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. Journal of Clinical Oncology. 29(7). 789–796. 310 indexed citations

19.

O’Brien, Susan, Ellin Berman, Hossein Borghaei, et al.. (2009). Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 7(9). 984–1023. 175 indexed citations

20.

Gotlib, Jason & Peter L. Greenberg. (2003). Novel Biospecific Agents for the Treatment of Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network. 1(4). 473–480. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact